TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 14, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 22
- 0 vs. Q1 2023
- Portfolio value
- $609.8M
- +$96.8M (+18.9%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 2,448,829 | $96.3M | 15.8% | −2,692,289−52.4% | Reduced | History |
| GERNGeron Corp | COM | 23,589,779 | $75.7M | 12.4% | +5,824,566+32.8% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 5,631,042 | $66.7M | 10.9% | +2,000,000+55.1% | Added | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 3,113,600 | $52.9M | 8.7% | 00.0% | Unchanged | – |
| JBIOJade Biosciences, Inc. | COM | 2,201,274 | $37.8M | 6.2% | +1,120,000+103.6% | Added | History |
| ICVXIcosavax, Inc. | COM | 3,703,704 | $36.8M | 6.0% | +3,703,704 | New | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 149,917 | $34.6M | 5.7% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $33.9M | 5.6% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 3,395,495 | $30.6M | 5.0% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 815,724 | $26.8M | 4.4% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 1,650,150 | $18.6M | 3.0% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $15.1M | 2.5% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 350,000 | $14.5M | 2.4% | 00.0% | Unchanged | History |
| IMVTImmunovant, Inc. | COM | 654,853 | $12.4M | 2.0% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $11.6M | 1.9% | 00.0% | Unchanged | History |
| ANTXAN2 Therapeutics, Inc. | COM | 1,289,320 | $11.0M | 1.8% | +1,289,320 | New | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $8.86M | 1.5% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 300,000 | $7.90M | 1.3% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 486,795 | $6.28M | 1.0% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 529,839 | $5.49M | 0.9% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $3.51M | 0.6% | +26,574+2.1% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 253,069 | $2.60M | 0.4% | 00.0% | Unchanged | History |
Sold out since Q1 2023 (2)
Positions held at the end of Q1 2023 that are gone from this filing.